Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer.

ABSTRACT:

Background and objectives

Brigatinib is an oral tyrosine kinase inhibitor approved in multiple countries for the treatment of patients with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer who have progressed on or are intolerant to crizotinib. We report a population pharmacokinetic model-based analysis for brigatinib.

Methods

Plasma concentration-time data were collected from 442 participants (105 healthy volunteers and 337 patients with cancer) who received single or multiple doses of oral brigatinib in one of five trials. Data were analyzed using non-linear mixed-effects modeling (NONMEM software version 7.3).

Results

Brigatinib plasma concentrations were best described by a three-compartment model with a transit compartment input (number o

SUBMITTER: Gupta N 

PROVIDER: S-EPMC7862202 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature